Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(20%)
Results Posted
300%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_3
1
20%
Ph phase_4
1
20%
Ph phase_2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed120%
not_yet_recruiting120%
recruiting120%
terminated240%

Recent Activity

1 active trials
Showing 5 of 5
recruitingnot_applicable

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

NCT07483385
not_yet_recruitingphase_4

A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag

NCT06426043
terminatedphase_2

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

NCT01054443
terminatedphase_2

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT01129024
completedphase_3

Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

NCT02389621

Clinical Trials (5)

Showing 5 of 5 trials
NCT07483385Not Applicable

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
NCT06426043Phase 4

A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag

Not Yet Recruiting
NCT01054443Phase 2

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Terminated
NCT01129024Phase 2

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

Terminated
NCT02389621Phase 3

Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5